PT  - JOURNAL ARTICLE
AU  - Pilbeam, Caitlin
AU  - Malden, Deborah
AU  - Newell, Katherine
AU  - Dagens, Andrew
AU  - Kennon, Kalynn
AU  - Michelen, Melina
AU  - Gobat, Nina
AU  - Sigfrid, Louise
TI  - Accessibility, inclusivity, and implementation of COVID-19 clinical management guidelines early in the pandemic: a global survey
AID  - 10.1101/2021.03.31.21254680
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.31.21254680
4099  - http://medrxiv.org/content/early/2021/04/02/2021.03.31.21254680.short
4100  - http://medrxiv.org/content/early/2021/04/02/2021.03.31.21254680.full
AB  - Background With a rapidly changing evidence base, high-quality clinical management guidelines (CMGs) are key tools for aiding clinical decision making and increasing access to best available evidence-based care. A rapid review of COVID-19 CMGs found that most lacked methodological rigour, overlooked many at-risk populations, and had variations in treatment recommendations. Furthermore, social science literature highlights the complexity of implementing guidelines in local contexts where they were not developed and the resulting potential to compound health inequities. The aim of this study was to evaluate access to, inclusivity of, and implementation of Covid-19 CMGs in different settings.Methods A cross-sectional survey of clinicians worldwide from 15 June to 20 July 2020, to explore access to and implementation of Covid-19 CMGs and treatment and supportive care recommendations provided. Data on accessibility, inclusivity, and implementation of CMGs. were analyzed by geographic location.Results Seventy-six clinicians, from 27 countries responded, 82% from high-income countries, 17% from low-middle income countries. Most respondents reported access to Covid-19 CMG and confidence in implementation of these. However, many respondents, particularly from LMICs reported barriers to implementation, including limited access to treatments and equipment. Only 20% of respondents reported having access to CMGs covering care for children, 25% for pregnant women and 50% for older adults (>65 years). Themes emerging were for CMGs to include recommendations for different at-risk populations, and settings, include supportive care guidance, be readily updated as evidence emerges, and CMG implementation supported by training, and access to treatments recommended.Conclusion Our findings highlight important gaps in Covid-19 CMG development and implementation challenges during a pandemic, particularly affecting different at-risk populations and lower resourced settings., to improve access in evidence-based care recommendations during an emergency. The findings identifies an urgent need for an improved framework for CMG development, that is inclusive and adaptable to emerging evidence and considers contextual implementation support, to improve access to evidence-based care globally.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/5mexc/ Funding StatementThis work was supported by the UK Foreign, Commonwealth and Development Office, Wellcome [215091/Z/18/Z], and the Bill & Melinda Gates Foundation [OPP1209135]; and PREPARE funded by the European Commission framework 7 [602525]. CP is funded by the UKRI/NIHR 2019-nCoV Rapid Response Call (Grant No. NIHR200907). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care or Public Health England.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was performed in accordance with the Declaration of Helsinki, and was given an exemption from ethical review by the Oxford Tropical Research Ethics Committee (OXTREC) on 16 April 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full dataset generated and analysed during the current study is available from the corresponding author on reasonable request.